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Two-compartment tumor metabolism

Autophagy in the tumor microenvironment and oxidative
mitochondrial metabolism (OXPHOS) in cancer cells
Ahmed F. Salem,1-3 Diana Whitaker-Menezes,1,2 Zhao Lin,1,2 Ubaldo E. Martinez-Outschoorn,1,2,4 Herbert B. Tanowitz,5
Mazhar Salim Al-Zoubi,1,2 Anthony Howell,6 Richard G. Pestell,1,2,4 Federica Sotgia1,2,6,* and Michael P. Lisanti1,2,4,6,*
1
The Jefferson Stem Cell Biology and Regenerative Medicine Center; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; 2Departments of Stem Cell
Biology & Regenerative Medicine, and Cancer Biology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; 3Department of Molecular Drug Evaluation;
Division of Biochemistry; National Organization for Drug Control and Research; Giza, Egypt; 4Department of Medical Oncology; Kimmel Cancer Center; Thomas Jefferson
University; Philadelphia, PA USA; 5Departments of Pathology and Medicine; Albert Einstein College of Medicine; Bronx, NY USA; 6Manchester Breast Centre & Breakthrough
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University of Manchester; Manchester, UK
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Previously, we proposed a new paradigm to explain the compartment-specific role of autophagy in tumor metabolism. In
this model, autophagy and mitochondrial dysfunction in the tumor stroma promotes cellular catabolism, which results in
the production of recycled nutrients. These chemical building blocks and high-energy “fuels” would then drive the anabolic
growth of tumors, via autophagy resistance and oxidative mitochondrial metabolism in cancer cells. We have termed this
new form of stromal-epithelial metabolic coupling: “two-compartment tumor metabolism.” Here, we stringently tested
this energy-transfer hypothesis, by genetically creating (1) constitutively autophagic fibroblasts, with mitochondrial
dysfunction or (2) autophagy-resistant cancer cells, with increased mitochondrial function. Autophagic fibroblasts
were generated by stably overexpressing key target genes that lead to AMP-kinase activation, such as DRAM and LKB1.
Autophagy-resistant cancer cells were derived by overexpressing GOLPH3, which functionally promotes mitochondrial
biogenesis. As predicted, DRAM and LKB1 overexpressing fibroblasts were constitutively autophagic and effectively
promoted tumor growth. We validated that autophagic fibroblasts showed mitochondrial dysfunction, with increased
production of mitochondrial fuels (L-lactate and ketone body accumulation). Conversely, GOLPH3 overexpressing breast
cancer cells were autophagy-resistant, and showed signs of increased mitochondrial biogenesis and function, which
resulted in increased tumor growth. Thus, autophagy in the tumor stroma and oxidative mitochondrial metabolism
(OXPHOS) in cancer cells can both dramatically promote tumor growth, independently of tumor angiogenesis. For the
first time, our current studies also link the DNA damage response in the tumor microenvironment with “Warburg-like”
cancer metabolism, as DRAM is a DNA damage/repair target gene.

Introduction
Autophagy is a conserved process of “self-eating” of both proteins
and cell organelles. This process is triggered as an adaptation to
cellular stress, which is caused by several factors, such as starvation, hypoxia, oxidative stress and DNA damage. Autophagy is
initiated when the autophagosome, a double-membrane vesicle,
engulfs cytoplasmic organelles. Autophagosomes fuse with lysosomes, which digests the vesicle’s contents.1 If excessive numbers
of autophagic vacuoles accumulate, programmed cell death may
be initiated.1
The complex role of autophagy in tumorigenesis has led
many researchers to recognize that autophagy exhibits both
tumor-promoting, as well as tumor-suppressing, activities.2-5 To

resolve this long-standing paradox, our laboratory has offered
a new model to better explain the compartment-specific role of
autophagy in tumor progression. In this simplistic model, we
have proposed autophagy acts as a tumor suppressor when it
takes place in epithelial cancer cells; conversely, autophagy acts
as a tumor promoter when it occurs in cancer-associated fibroblasts (CAFs).6
Our previous studies indicate that during tumor growth, cancer cells release reactive oxygen species (ROS) into the tumor
microenvironment.7 This has been shown to initiate a loss of
caveolin-1 (Cav-1) protein expression via the onset of autophagy
and mitophagy in stromal fibroblasts.8,9 Subsequently, these
autophagic cancer-associated fibroblasts, with reduced number
of mitochondria, shift their metabolism toward glycolysis and
produce high-energy mitochondrial fuels, including L-lactate,
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Figure 1. DRAM-overexpressing fibroblasts show the induction of
autophagy: Immunobotting. hTERT-BJ1 immortalized human fibroblasts were transduced with a lentiviral vector encoding DRAM, or the
vector-alone control (Lv-105). After selection for puromycin resistance,
the stable fibroblast cell lines were used to prepare protein lysates,
which were then subjected to immunoblot analysis with specific
antibody probes. (A) Immunoblot analysis validates the expression of
DRAM. (B) Note that four autophagy markers (BNIP3, Beclin1, LAMP1
and Cathepsin B) were all upregulated in response to DRAM expression,
consistent with the induction of autophagy. In (A and B), immunoblotting with β-actin is shown as a control for equal protein loading.

show a loss of p53-dependent autophagy. Moreover, DRAM
expression was found to be silenced by hyper-methylation at its
CpG islands in multiple tumor types.24 Recently, other regulators
of DRAM, such as p73, JNK and E2F1, have been identified.25-27
Another critical regulator of cellular stress and the autophagic response is liver kinase B1 (LKB1), a serine/threonine kinase
that is mutated in Peutz-Jeghers Syndrome.28 Peutz-Jeghers is rare
autosomal-dominant harmatoma syndrome; carriers can also
develop gastrointestinal, pancreatic and lung tumors.29 LKB1
activates AMP-activated protein kinase (AMPK) by phosphorylation at the AMP-kinase theronine residue (T172). AMP-kinase
functions as an energy sensor and tightly controls a variety of
catabolic processes.28,30 In mammals, AMPK is a hetero-trimer
consisting of three subunits: α (catalytic), β and γ (non-catalytic
parts).31,32 Upon activation, AMPkinase induces autophagy via
two main signaling pathways: (1) inhibition of the mammalian
target of rapamycin-1 (mTOR1) complex, an autophagy inhibitor, and (2) interaction with unc-51-like kinase 1 (ULK1), a key
initiator of autophagy.28,33
GOLPH3/MIDAS/GPP34 is a mitochondrial protein which
critically regulates mitochondrial lipid biogenesis and, hence,
mitochondrial mass.34 It is normally upregulated in skeletal
muscle cells in response to mitochondrial dysfunction as a compensatory mechanism to promote mitochondrial biogenesis.34
GOLPH3 shuttles between the Golgi apparatus and mitochondria to increase the delivery of mitochondrial phospho-lipids
(such as cardiolipin), thereby increasing overall mitochondrial
mass.34 Recently, Scott et al. have found that GOLPH3 is amplified in multiple types of human cancer.35 Also, they proposed
that GOLPH3 may function as an oncogene, via activation of the
mTOR1 signaling pathway.35
Here, we genetically manipulated the expression of DRAM,
LKB1 and GOLPH3 to dissect the compartment-specific role
of autophagy and mitochondrial biogenesis in tumor growth.
Autophagic fibroblasts, overexpressing DRAM or LKB1, showed
AMP-kinase activation and promoted tumor growth in a paracrine fashion that could not be accounted for by neo-vascularization. In addition, autophagy-resistant cancer cells, overexpressing
GOLPH3, showed mTOR-activation and an increase in mitochondrial function, resulting in a significant increase in tumor
growth. Thus, our current results are consistent with the idea that
(1) catabolism in the tumor microenvironment (e.g., autophagy
and mitochondrial dysfunction) and (2) mitochondrial biogenesis/autophagy resistance in epithelial cancer cells, both enhance
anabolic tumor growth.
In summary, autophagy functions as a tumor promoter or a
tumor suppressor, depending on its compartmental or cellular
localization. Our findings indicate that autophagy is a tumor
promoter when it occurs in cancer-associated fibroblasts; conversely, autophagy functions as a tumor suppressor when it takes
place in cancer cells.
This general model is also consistent with our previous findings showing that activated HIF-1α (a major positive regulator of
autophagy) functions as a tumor promoter in cancer-associated
fibroblasts and as a tumor suppressor in epithelial cancer cells,36
both independently of tumor angiogenesis.

© 2012 Landes Bioscience.
Do not distribute.

ketone bodies (3-hydroxy-butyrate), glutamine and free fatty
acids.10-12
Eventually, these secreted metabolites are consumed by
neighboring cancer cells, which use these metabolites to “fuel”
mitochondrial oxidative metabolism (OXPHOS).11,13 We have
termed this energy-transfer model: (1) the “autophagic tumor
stroma model of cancer” or (2) “two-compartment tumor
metabolism”.11,14
Moreover, we and other laboratories have established that a
loss of stromal caveolin-1 (Cav-1) expression in cancer-associated
fibroblasts is a biomarker for poor prognosis in human breast
and prostate cancers as well as in patients with melanoma.15-20
As Cav-1 undergoes lysosomal degradation during autophagy
in fibroblasts, a loss of stromal Cav-1 is a functional marker for
autophagy, mitophagy and mitochondrial dysfunction in the
tumor microenvironment.9 As stated above, this catabolic microenvironment would then provide energy to sustain the anabolic
growth of aggressive cancer cells, explaining its strong association
with a poor prognosis.6,20,21
A key component of the cellular stress response is p53, which is
mutated and/or deleted in > 50% of human cancers.22,23 Nuclear
p53 can transactivate an array of autophagy inducers, such as
damage-regulated autophagy modulator (DRAM).22 DRAM is
a recently discovered lysosomal protein that is highly conserved
and induces p53-dependent autophagy.24 DRAM-deficient cells
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Results
DRAM activates autophagy in fibroblasts, resulting in a loss of Cav-1
protein expression and mitochondrial
dysfunction, driving AMP-kinase activation. We previously established that a
loss of caveolin-1 (Cav-1) in the tumor
stroma correlates with poor prognosis
in human breast cancers. Interestingly,
genome-wide transcriptional profiling
of Cav-1-deficient tumor stroma reveals
the induction of an autophagic program.
Thus, one hypothesis is that autophagic
fibroblasts may enhance tumor growth.
To test this hypothesis directly, we
generated fibroblasts with a constitutive
autophagic phenotype. For this purpose,
we chose to use DRAM (damage-regulated autophagy modulator) to upreguFigure 2. DRAM-overexpressing fibroblasts show the induction of autophagy: Immuno-fluoreslate autophagy in stromal fibroblasts.
cence during co-culture. DRAM-overexpressing fibroblasts or the corresponding vector-alone conDRAM is a lysosomal protein that is
trol fibroblasts (Lv-105) were co-cultured with MDA-MB-231-GFP+ cells (GREEN) for a period of 3 d.
Note that DRAM-expressing fibroblasts clearly showed increased expression of autophagy markers
trans-activated by p53 and is critical for
(LAMP1 and Beclin1) by immuno-fluorescence microscopy (red, indicated by white arrows). Nuclei
p53-dependent autophagy.
were visualized by counter-staining with Hoechst-33258 (blue).
Briefly, immortalized human fibroblasts (hTERT-BJ1 cells) were stably transfected with DRAM (Fig. 1A). Then, we examined is also known to serve as a feed-forward mechanism for the inducthe expression of a panel of autophagy markers in DRAM- tion of autophagy, perpetuating a vicious cycle of autophagy and
overexpressing fibroblasts. Figure 1B shows that four autophagy mitochondrial dysfunction.
DRAM-overexpressing fibroblasts enhance tumor growth.
markers (BNIP3, Beclin1, LAMP1 and Cathepsin B) were all
upregulated in response to DRAM expression, consistent with We hypothesized that autophagic fibroblasts will actively prothe induction of autophagy. Similar results were also obtained mote tumor growth via the production of recycled nutrients and
when fibroblasts were co-cultured with human breast cancer cells chemical building blocks derived from cellular catabolism. To
(MDA-MB-231-GFP+); DRAM-expressing fibroblasts clearly test this hypothesis, DRAM-overexpressing fibroblasts were coshowed increased expression of autophagy markers (LAMP1 and injected with breast cancer cells (MDA-MB-231-GFP+) into the
Beclin1) by immuno-fluorescence (Fig. 2). Importantly, DRAM- flanks of athymic nude mice flank. At 4 weeks post-injection,
overexpressing fibroblasts also showed a loss of Cav-1 expression tumors grown in the presence of DRAM fibroblasts showed a
~2-fold increase in tumor growth (as measured by either tumor
as predicted, likely due to the induction of autophagy (Fig. 3).
As BNIP3 is a marker of mitophagy, we also investi- weight or volume) (Fig. 6A).
To examine the possible contribution of angiogenesis to
gated the status of mitochondrial OXPHOS (complexes I–V).
Interestingly, DRAM-overexpressing fibroblasts showed signifi- increase the tumor growth, we next immunostained frozen
cant reductions in components of complex I, III and IV (Fig. 4A) tumor sections with anti-CD31 antibodies, and then selected
by immunoblotting, consistent with a mitophagy phenotype. 8–10 random fields from four tumors (of each experimental
Increased L-lactate and ketone production are classical hallmarks group) to quantify tumor vascularization. Although tumors
of mitochondrial dysfunction. Similarly, DRAM-overexpressing grown with DRAM fibroblasts show a slight increase in vessel
fibroblasts showed dramatic increases in L-lactate (> 3-fold) and density (Fig. 6B), this small difference could not account for the
β-hydroxy-butyrate (~3–5-fold) production, which was further observed 2-fold increase in tumor growth.
Thus, our data are more consistent with the hypothesis that
accentuated by starvation (Fig. 4B–D).
Since mitochondrial dysfunction leads to increases in AMP catabolism in the tumor stroma can “fuel” the anabolic growth of
levels (due to decreased ATP), we checked the status of AMP- cancer cells, via stromal-epithelial metabolic coupling.
LKB1-mediated AMP-kinase activation in cancer-associated
kinase activation. Figure 5 shows that AMP kinase is indeed
hyperactivated in DRAM-overexpressing fibroblasts, indicative fibroblasts drives autophagy and promotes tumor growth. AMP
kinase is a master regulator of cell metabolism.28 AMP-kinase
of a loss of mitochondrial function.
Thus, DRAM fibroblasts show the induction of autophagy, activation triggers numerous catabolic pathways, such as glycolymitophagy and mitochondrial dysfunction with AMP-kinase sis, autophagy and mitophagy. LKB1 is an upstream kinase that
activation. Consistent with our findings, AMP-kinase activation directly phosphorylates AMP kinase, resulting in its activation,

© 2012 Landes Bioscience.
Do not distribute.

www.landesbioscience.com

Cell Cycle

2547

Figure 3. DRAM activates autophagy in fibroblasts, resulting in loss of
Cav-1 protein expression. Note that DRAM-overexpressing fibroblasts
also showed a loss of Cav-1 expression, as predicted, likely due to the
induction of autophagy. Immunoblotting with β-actin is shown as a
control for equal protein loading.

which then drives autophagy when AMP levels rise due to mitochondrial dysfunction.30
To assess whether AMP-kinase activation in stromal fibroblasts is sufficient to promote tumor growth, we next generated
hTERT-BJ1 fibroblasts overexpressing wild-type LKB1. As critical negative controls, we also generated matched fibroblast cell
lines overexpressing a kinase-dead (KD) form of LKB1 (K78I)
or the vector-alone control (pBABE-puro). Kinase-dead LKB1
may be expected to show a dominant-negative phenotype, as it
should retain the ability to bind to and sequester its substrate,
AMP kinase.
Figure 7A shows that both forms of LKB1 (WT and KD)
were well expressed in hTERT-BJ1 fibroblasts, although the KD
mutant (K78I) showed higher steady-state expression levels.
Importantly, wild-type LKB1 functionally induced the activation of AMP-kinase phosphorylation as seen by immunoblot
analysis, with phospho-specific antibody probes (Fig. 7B), and
was sufficient to upregulate autophagy markers (such as BNIP3
and LC3-I/II) (Fig. 7C).
To determine whether autophagic fibroblasts with constitutive AMP-kinase activation can promote tumor growth,
LKB1-overexpressing fibroblasts were co-injected with MDA-MB231-GFP+ cells into the flanks of athymic nude mice (Fig. 8A). As
predicted, autophagic fibroblasts overexpressing wild-type LKB1
significantly promoted tumor growth (by ~2-fold), while fibroblasts expressing kinase-dead LKB1 dramatically retarded tumor
growth (by > 2.5-fold) (Fig. 8B). Moreover, if we compare wildtype vs. kinase-dead LKB1 fibroblast-driven tumor growth, there
was a ~3–5-fold reduction in tumor growth in the absence of stromal activation of AMP kinase. Importantly, these striking changes
in tumor growth did not correlate with large increases or decreases
in neo-vascularization, as measured by CD31 immunostaining,
ruling out angiogenesis as the primary cause (Fig. 8C).
Consistent with the idea that AMP-kinase activation in
cancer-associated fibroblasts is strictly required to promote
tumor growth, recombinant expression of AMP-kinase isoforms
(AMPK α1 or α2) alone in hTERT fibroblasts was not sufficient
to promote tumor growth (Fig. 9). Thus, AMP-kinase activation, mediated by LKB1, is specifically required to generate this
phenotype.
GOLPH3 confers autophagy resistance and promotes mitochondrial biogenesis in breast cancer cells, enhancing anabolic

tumor growth. GOLPH3 shuttles between the Golgi apparatus and mitochondria to functionally promote mitochondrial
biogenesis.34,35 Recently, Scott et al. identified GOLPH3 as an
oncoprotein, which is genetically amplified in several tumors.35
Moreover, GOLPH3 activates the autophagy inhibitor,
mTOR.35 mTOR is a direct regulator of mitochondria function,
and rapamycin (an mTOR1 inhibitor) decreases mitochondrial
capacity and oxygen consumption,37 likely via the induction of
autophagy.
Here, we overexpressed GOLPH3 in MDA-MB-231 breast
cancer cells to examine the functional effects of autophagy
resistance and enhanced mitochondrial biogenesis on tumor
growth. Figure 10A shows that GOLPH3 was successfully stably expressed, as detected using antibodies directed against the
HA-epitope tag. Then, we validated that GOLPH3 overexpression activates mTOR-signaling (Fig. 10B) and confers autophagy resistance (Fig. 10B and C) using three autophagy markers
(namely, cathepsin B, BNIP3 and LC3). Finally, GOLPH3 overexpression in MDA-MB-231 cells also increased MitoTracker
staining by > 2-fold, consistent with an increase in mitochondrial
biogenesis and/or function (Fig. 11A).
Finally, we injected GOLPH3-overexpressing cancer cells
into the flanks of athymic nude mice. At 4 weeks post-injection,
GOLPH3 tumors showed a 3-fold increase in growth, relative
to the vector-alone control (Fig. 11B). However, no significant
increases in angiogenesis were noted, as visualized by CD31
immunostaining (Fig. 11C).
Importantly, the effects of GOLPH3 on tumorigenesis are
compartment-specific, as overexpression of GOLPH3 in hTERT
fibroblasts increased MitoTracker activity by > 1.5-fold but did
not significantly affect tumor growth when GOLPH3-fibroblats
were co-injected with MDA-MB-231 breast cancer cells (Fig. S1).
Thus, we conclude that the tumor-promoting and tumorsuppressing effects of autophagy are cell type-specific and are not
intrinsic property of the process itself. Also, tumor suppressors
(such as LKB1 and AMP-kinase) could function as tumor promoters when activated in cancer-associated fibroblasts Therefore, the
compartment-specific role of tumor suppressor and promoter genes
should be carefully studied in both cancer cells and adjacent stromal cells.

© 2012 Landes Bioscience.
Do not distribute.
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Discussion
Autophagy in the tumor microenvironment: Does stromal
catabolism fuel anabolic tumor growth? Recently, we showed
that a loss of Cav-1 expression in the tumor stroma predicts early
tumor recurrence, lymph-node metastasis, tamoxifen resistance
and overall poor clinical outcome in women with breast cancer.17,18 Molecular profiling of Cav-1-deficient tumor microenvironment in breast cancer patients demonstrates the induction of
target genes associated with aging, DNA damage, inflammation
and especially autophagy, all of which are known to be associated with exposure to hydrogen peroxide (due to activation of
key transcription factors, namely, HIF1 and NFκB).38 Thus,
one idea is that oxidative stress-induced catabolism in the tumor
microenvironment fuels the anabolic growth of cancer cells. We

Cell Cycle
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Figure 4. DRAM activates autophagy in fibroblasts, driving mitochondrial dysfunction. (A) OXPHOS immunoblotting. Given the upregulation of
BNIP3 (a marker of mitophagy), we also investigated the status of mitochondrial OXPHOS (complexes I–V). Note that DRAM-overexpressing fibroblasts
showed significant reductions in components of OXPHOS complexes I, III and IV, consistent with a mitophagy phenotype. Immunoblotting with
β-actin is shown as a control for equal protein loading. (B) L-lactate production. hTERT fibroblasts were plated in 12-well dishes in complete media, at a
cell density of 1 x 105 fibroblasts per well. The next day, the media was changed to fresh DMEM supplemented with 2% FBS. After 48 h, the media was
collected, and L-lactate was immediately assayed using the EnzyChrom L-lactate assay kit (BioAssay, Inc.), according to the manufacturer’s protocol.
Cells were then washed, trypsinized and counted using a hemocytometer. Note that DRAM-overexpressing fibroblasts show a > 3-fold increase in
L-lactate accumulation in the tissue culture media. (C and D) Ketone production. hTERT fibroblasts were plated in 12-well dishes in complete media
at a cell density of 1 x 105 fibroblasts per well. The next day, the media was changed to fresh DMEM supplemented with 2% FBS. After 72 h, the media
was collected and ketones were immediately assayed using a β-hydroxy-butyrate (β-HB) Assay Kit (Biovision, Inc.), according to the manufacturer’s
protocol. Alternatively, cells were starved for 6 h by adding warm HBSS-supplemented with 40 mM HEPES. After starvation, the HBSS was collected
and ketones were measured. Cells were washed, trypsinized and counted using a hemocytometer. Note that DRAM-overexpressing fibroblasts show a
> 3-fold increase in ketone body accumulation in the tissue culture media (C), and this effect was accentuated further by starvation (D).

previously termed this new model of stromal-epithelial metabolic
coupling the “autophagic tumor stroma model of cancer.” In
accordance with this hypothesis, other laboratories have shown
that the expression of autophagy-associated genes in the tumor
stroma is associated with more aggressive tumor behavior and
poor clinical outcome.39-41
Here, to genetically test this hypothesis, we chose to generate
various pre-clinical models of autophagic cancer-associated fibroblasts via the overexpression of autophagy genes and AMP-kinase
activators (DRAM and LKB1).
Autophagy (Beclin1, LAMP1 and Cathepsin B) and mitophagy (BNIP3) genes were specifically upregulated by DRAM
expression in hTERT-immortalized fibroblasts. Cav-1 protein
expression and mitochondrial OXPHOS complexes were also
downregulated in DRAM-overexpressing fibroblasts, reflecting

www.landesbioscience.com

Figure 5. DRAM-overexpressing fibroblasts show AMP-kinase activation. Mitochondrial dysfunction leads to increases in AMP levels (due to
decreased ATP). Thus, we examined the status of AMP-kinase activation.
Note that AMP-kinase is indeed hyperactivated in DRAM-overexpressing fibroblasts, consistent with a loss of mitochondrial function. Immunoblotting with β-actin is shown as a control for equal protein loading.
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for the first time that LKB1 acts as a tumor promoter
in cancer-associated fibroblasts.
These findings indicate that the specific role of
tumor suppressors needs be re-evaluated according
to their expression in a given cell-type or metabolic
tumor compartment (e.g., stromal cells vs. epithelial
cancer cells).
Mitochondrial biogenesis and autophagy resistance in cancer cells promotes increased tumor
growth. Next, we tested the hypothesis that mitochondrial biogenesis and autophagy resistance in
epithelial cancer cells would also enhance anabolic
tumor growth. For this purpose, we chose to overexpress GOLPH3 in human breast cancer cells (MDAMB-231-GFP+). GOLPH3 is a recently discovered
oncoprotein that activates the mTOR-signaling
pathway.35 As predicted, GOLPH3-overexpressing
MDA-MB-231 cells showed increased mTOR phosphorylation and significant reductions in both
autophagy and mitophagy markers (LC3, Cathepsin
B and BNIP3), consistent with the onset of autophagy resistance. In addition, GOLPH3-overexpressing
MDA-MB-231 cells also showed a 2.3-fold increase
in MitoTracker activity, indicative of an increase in
mitochondrial biogenesis and/or function. In support
Figure 6. DRAM-overexpressing fibroblasts enhance tumor growth, without a
of the hypothesis that mitochondrial biogenesis and
dramatic increase in angiogenesis. (A) DRAM-overexpressing fibroblasts were
autophagy resistance will promote tumor aggressiveco-injected together with breast cancer cells (MDA-MB-231-GFP+) into the flanks of
ness, GOLPH3-overexpressing MDA-MB-231 cells
athymic nude mice flank. At 4 weeks post-injection, tumors grown in the presence
of DRAM fibroblasts showed an ~2-fold increase in tumor growth (as measured by
showed a 3-fold increase in tumor growth. Thus, we
either tumor weight or volume). p-values are as shown. n = 10 per experimental
demonstrate for the first time that GOLPH3 regulates
group. (B) Although tumors grown with DRAM fibroblasts show a slight increase in
both autophagy and mitochondrial activity. As such,
CD31-positive vessel density (~18%), this small difference could not account for the
increased mitochondrial biogenesis or function may
observed 2-fold increase in tumor growth. Thus, our data are more consistent with
protect cancer cells against the induction of autophthe hypothesis that catabolism in the tumor stroma can “fuel” the anabolic growth
of cancer cells via stromal-epithelial metabolic coupling.
agy, by preventing AMP-kinase activation.
Our current hypothesis is also consistent with the
general consensus view that cancer cells benefit from
the onset of autophagy/mitophagy and mitochondrial dysfunc- evading the autophagy (self-eating) response.43-45 There are two
tion. AMP-kinase activation was also observed, indicative of known molecular mechanism(s) that cancer cells use to drive
the onset of metabolic dysfunction. Most importantly, consis- autophagy resistance: (1) hyperactivation of mTOR signaling,
tent with our hypothesis, DRAM-overexpressing fibroblasts which is a central network or pathway that can inhibit autophagy
co-injected with MDA-MB-231 breast cancer cells showed a and (2) the deletion and/or suppression of autophagy-inducing
2-fold increase in tumor growth relative to vector-alone control genes, such as LKB1, Beclin1, PTEN, tuberous sclerosis complex
(TSC) 1 and 2, DAPK-1 and wild-type p53.43-45
fibroblasts.
Quantitatively similar results were obtained by constituA schematic diagram summarizing our new findings is pretive activation of AMP kinase via overexpression of LKB1, its sented in Figure 12. Thus, targeting autophagy and/or mitochonupstream activator. LKB1 normally phosphorylates AMP- drial function in cancer cells and the tumor microenvironment
kinase-α on Thr-172, which initiates the activation of several is an important strategy for the development of new prognosmetabolic pathways, such as autophagy, mitophagy and glycoly- tic markers and novel therapeutic interventions. However, it is
sis, during cellular stress.28,42 Here, we generated constitutively important to note that tumor suppressor genes can also promote
autophagic fibroblasts by overexpressing wild-type (WT) LKB1. tumor growth when overexpressed in the tumor stromal microAs two critical negative control(s), we also generated (1) fibro- environment. Thus, interfering with “stromal-epithelial metablasts overexpressing a kinase-dead (KD) form of LKB1, as well bolic coupling” will help in the fight against cancer, as it will
as (2) vector-alone fibroblasts. Strikingly, fibroblasts overexpress- “cut-off the fuel supply” to cancer cells.
ing WT-LKB1 increased tumor growth by ~2-fold, relative to
Developing autophagy-based therapies for the treatment
the vector-alone control. Conversely, fibroblasts overexpressing of cancer patients. The idea of targeting autophagy as a treatKD-LKB1 reduced tumor growth by ~2.5-fold. Thus, we show ment for human cancers has now been embraced by the medical
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Figure 7. LKB1 activates AMP kinase in fibroblasts, resulting in the onset of autophagy. To determine if AMP-kinase activation in stromal fibroblasts is
sufficient to promote tumor growth, we generated hTERT-BJ1 fibroblasts overexpressing wild-type LKB1. As critical negative controls, we also generated matched fibroblast cell lines overexpressing a kinase-dead (KD) form of LKB1 (K78I), or the vector-alone control (pBABE-puro). (A) Note that both
forms of LKB1 (WT and KD) were well-expressed in hTERT-BJ1 fibroblasts, although the KD mutant (K78I) showed higher steady-state expression levels.
(B) Wild-type LKB1 functionally induced the activation of AMP-kinase phosphorylation as seen by immunoblot analysis, with phospho-specific antibody probes. (C) Wild-type LKB1 was sufficient to upregulate autophagy markers (such as BNIP3 and LC3-I/II). In (A–C), immunoblotting with β-actin is
shown as a control for equal protein loading.

Figure 8. LKB1-mediated AMP-kinase activation in cancerassociated fibroblasts drives autophagy and promotes tumor
growth. To determine whether autophagic fibroblasts with
constitutive AMP-kinase activation can promote tumor growth,
LKB1-overexpressing fibroblasts were co-injected with MDAMB-231-GFP+ cells into the flanks of athymic nude mice. As
predicted, autophagic fibroblasts overexpressing wild-type
(WT) LKB1 significantly promoted tumor growth (by ~2-fold),
while fibroblasts expressing kinase-dead (KD) LKB1 dramatically
retarded tumor growth (by > 2.5-fold) (A and B). p-values are as
shown. n = 10 per experimental group. (A) The time course of
tumor growth (volume) is shown up to 3.5 weeks post-injection.
(B) Tumor growth (weight and volume) is shown after tumor excision, on day 25 post-injection. (C) These striking changes in tumor growth did not correlate with large increases or decreases
in neo-vascularization, as measured by CD31 immunostaining,
ruling out angiogenesis as the primary cause.
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oncology community. However, we show here that the
regulation of autophagy in tumors is highly celltype- and
compartment-specific.
More specifically, our current findings show that
autophagy induction in the tumor microenvironment promotes tumor growth, while autophagy resistance in cancer cells also enhances tumor growth. Thus, inhibition of
autophagy in the tumor microenvironment should reduce
tumor growth, while induction of autophagy in cancer
cells should also inhibit tumor growth. These findings
explain the well-known “autophagy paradox” of cancer
therapy, that both autophagy inhibitors (chloroquine) and
autophagy inducers (rapamycin) can prevent or significantly reduce tumor growth.8,9
Rapamycin is an antibiotic that has been found to
inhibit mTOR1 and induce autophagy.46,47 Analogs of
rapamycin, temsirolimus and everolimus, have been
approved to treat renal cell carcinoma and mantle cell lymphoma.48 Also, GDC-0941 and NVP-BEZ235 are dual
inhibitors of mTOR1 and PI3K, which block the feedback loop resulting from mTOR1 inhibition.49 These two
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(DMEM), supplemented with 10% fetal bovine
serum in a 37°C humidified atmosphere containing 5% CO2, unless otherwise noted.
Cell line derivation. Lentiviral vectors. Lentiviral
particles were produced after 48 h of transfecting the
GeneCopoeia 293Ta lentiviral packaging cell line
with lentiviral plasmids [EX-NEG-Lv105 (puro)]
(empty vector), DRAM (EX-W1855-Lv105),
AMPK-alpha1 559-a.a. (EX-H0271-Lv105),
AMPK-alpha1 574-a.a. (EX-T8424-Lv105), or
AMPK-alpha2 (EX-C0433-Lv105) (all obtained
from GeneCopoeia, Inc.), using the Lenti-Pac
HIV Expression Packing Kit (GeneCopoeia, Inc.),
according to manufacturer’s recommendations.
Human immortalized fibroblasts were transduced
by lentivirus particles in the presence of 5 μg/ml of
Figure 9. Overexpression of AMP-kinase isoforms in fibroblasts is not sufficient to
Polybrene (Santa Cruz Biotech). Transduced cells
promote tumor growth. AMP-kinase overexpressing fibroblasts were co-injected with
were selected with 1.5 μg/ml of puromycin.
MDA-MB-231-GFP+ cells into the flanks of athymic nude mice. Note that recombinant
Retroviral vectors. Retroviral plasmids pBABEexpression of AMP-kinase isoforms (AMPK α1 or α2) alone in hTERT fibroblasts was not
sufficient to promote tumor growth. Thus, AMP-kinase activation, mediated by LKB1, is
puro (empty vector), LKB1 (pBABE-FLAG-LKB1,
specifically required to enhance tumor growth. The functional effects of expression of
Plasmid #8592), LKB1-KD (pBABE-FLAG-KD
two different isoforms of AMPK α1 was examined (559 amino acids vs. 574 amino acids).
LKB1, Plasmid #8593) and GOLPH3 (pBABENS, not significant. n = 10 per experimental group.
HA-GOLPH3, Plasmid #21687) (all obtained
from Addgene Inc.) were transfected into the
promising drugs have now entered phase II trials for breast cancer Phoenix Amphotropic packaging cell line using the FuGene6
treatment.49 Interestingly, temsirolimus and hydroxychloroquine reagent (Roche Molecular Biochemicals) according to the manu(HCQ) have been used in a phase I trial for treating refractory facturer’s instructions. After 48 h, virus-containing medium was
metastatic solid tumors (http://clinicaltrials.gov/ct2/show/ passed through a 0.45 μm filter and added to hTERT-BJ1 or
MDA-MB-231-GFP cells, in the presence of 5 μg/ml Polybrene.
NCT00909831).
Hydroxy-chloroquine (HCQ; an anti-malarial drug) inhib- Transduction was repeated the next day. Transduced cells were
its autophagy by disturbing the vacuolar H + ATPase respon- selected in the presence of 1.5 μg/ml (for hTERT-BJ1) and 2.0
sible for lysosomes acidification.50 A chloroquine-based clinical μg/ml (for MDA-MB-231-GFP+) puromycin.
trial for the treatment of early human breast cancers (DCIS
Immunoblot assays. Protein lysates were obtained by cell
lesions) is now ongoing: http://clinicaltrials.gov/ct2/show/ scraping into lysis buffer (10 mM Tris, pH 7.5, 150 mM NaCl,
NCT01023477.
1% Triton X-100 and 60 mM n-octylglucoside) containing protease inhibitors (Boehringer Mannheim). Samples were then
Materials and Methods
incubated on a rotating platform at 4°C and were centrifuged at
12,000x g for 10 min (at 4°C) to remove insoluble debris. Protein
Materials. Antibodies were purchased from the following com- concentrations were analyzed using the BCA reagent (Pierce).
mercial sources: Anti-DRAM [# sc-98654 (H-128); Santa Cruz Samples were separated by SDS-PAGE (10%-acrylamide) and
Biotech], anti-Cav-1 [#sc-894 (N-20); Santa Cruz Biotech], transferred to nitrocellulose. All subsequent wash buffers conanti-Beclin1 (for immuno-blot #NBP1-00085, Novus; for tained 10 mM Tris, pH 8.0, 150 mM NaCl, 0.1% Tween 20,
immunostaining #2026-1, Epitomics), anti-LAMP1 [#sc-17768 which was supplemented with 5% nonfat dry milk (Carnation)
(E-5); Santa Cruz Biotech], anti-BNIP-3 (#ab10433; Abcam), for the blocking solution and 1% bovine serum albumin (Sigma)
anti-Cathepsin B (#sc-13985 (FL-339); Santa Cruz Biotech), for the antibody diluent. Horseradish peroxidase-conjugated secanti-OXPHOS (#MS601; Mitosciences), anti-β actin (#A5441, ondary antibodies were used to visualize bound primary antibodSigma), anti-phospho-AMPK (#2531, Cell Signaling), anti- ies with an ECL detection kit (Pierce).
AMPK (#2532, Cell Signaling), anti-LKB (#sc-32245 (Ley 37D/
Immunofluorescence. Cancer cells (MDA-MB-231) and
G6); Santa Cruz Biotech), anti-mTOR (#2983; Cell Signaling), fibroblasts (hTERT-BJ1) were plated onto coverslips in 12-well
anti-phospho-mTOR (#2971; Cell Signaling) and anti-HA plates for 48 h in DMEM supplemented with 10% Nu serum.
(#16B12; Covance). Other reagents were purchased as follows: Then, cells were rinsed with PBS containing 0.1 mM CaCl2 and
Hoechst-33258 nuclear stain was from Sigma and Anti-fade 1 mM MgCl2 (PBS/CM) and fixed with 2% paraformaldehyde
reagent (#S2828) was from Invitrogen.
in PBS/CM for 30 min. After fixation, cells were washed three
Cell cultures. MDA-MB-231 cells (a human breast triple neg- times with PBS/CM and permeabilized with IF buffer (PBS/CM
ative cell line) and hTERT-BJ1 cells (an immortalized fibroblast with 0.1% Triton-X100 and 0.2% bovine serum albumin) for
cell line) were cultured in Dulbecco’s modified Eagle’s medium 10 min. Then, fixed cells were quenched with 50 mM NH4Cl in
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Figure 10. GOLPH3 overexpression in breast cancer cells confers mTOR activation and autophagy resistance. We overexpressed GOLPH3 in MDAMB-231 breast cancer cells, to examine its functional effects on mTOR activation and autophagy resistance. (A) Note that GOLPH3 was successfully stably expressed in MDA-MB-231 cells, as detected using antibodies directed against the HA-epitope tag. (B) Under basal cell culture conditions, GOLPH3
activates mTOR hyper-phosphorylation and a loss of cathepsin B expression. (C) Under conditions of starvation [4 h in HBSS (40 mM HEPES, pH 7.2, in
Hank’s Balanced Salt Solution)], GOLPH3 confers autophagy resistance, as evidenced by a loss of BNIP3 and LC3-I/II expression. In (A–C), immunoblotting with β-actin is shown as a control for equal protein loading.

© 2012 Landes Bioscience.
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Figure 11. GOLPH3 overexpression promotes mitochondrial biogenesis in breast cancer cells, enhancing anabolic tumor growth. (A) GOLPH3 overexpression in MDA-MB-231 cells increased MitoTracker staining by > 2-fold, consistent with an increase in mitochondrial biogenesis and/or function.
(B) We injected GOLPH3-overexpressing MDA-MB-231 cells into the flanks of athymic nude mice. At 4 weeks post-injection, GOLPH3 tumors showed
a 3-fold increase in growth, relative to the vector-alone control. p-values are as shown. n = 10 per experimental group. (C) No significant increases in
angiogenesis were noted, as visualized by CD31 immunostaining.

PBS/CM for 10 min, rinsed and incubated with anti-beclin-1 or
anti-LAMP1 antibodies for 1 h at room temperature. Cells were
washed with IF buffer and incubated with fluorescent secondary
antibodies (Molecular Probes) for 30 min. After washing, cells
were incubated with Hoechst-33258 for nuclear staining, rinsed
and mounted with ProLong Gold anti-fade (Molecular Probes).
Images were acquired with a Zeiss LSM510 Meta confocal microscope system and analyzed with Zeiss LSM Browser.
Mitochondrial activity studies. We stained cell lines with
MitoTracker Orange (CMTMRos; cat #M7510, Invitrogen,
Inc.) to measure mitochondrial activity, as stain accumulation
is dependent upon an intact mitochondrial membrane potential. Cells were cultured for 2 d in DMEM supplemented with
10% Nu serum. After 2 d, the cells were then incubated with
pre-warmed MitoTracker staining solution (diluted in serumfree DMEM to a final concentration of 25 nM) for 10 min at
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37°C. All subsequent steps were performed in the dark. Cells
were washed in PBS, trypsinized and re-suspended in 300 μL of
Binding Buffer (BD Biosciences). Cells were then analyzed by
FACS. Data analysis was performed using FlowJo 8.8 software.
Pre-clinical animal studies. All animals were maintained in a
pathogen-free environment/barrier facility at the Kimmel Cancer
Center at Thomas Jefferson University under National Institutes
of Health (NIH) guidelines. All animal protocols were approved
by the Institutional Animal Care and Use Committee (IACUC).
Tumor cells (MDA-MB-231-GFP+; 1 x 106 cells) were injected
alone or co-injected with hTERT-BJ1 fibroblasts (3 x 105 cells)
in 100 μl of sterile PBS into the flanks of athymic NCr nude
mice (NCRNU; Taconic Farms; 6–8 weeks of age). Mice were
sacrificed at 3–4 weeks post-injection; tumors were excised to
determine their weight and size, using electronic calipers. Tumor
volumes were calculated using the formula V = (x 2y)/2, where V
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day, the media was switched to DMEM containing 2% FBS.
After 48 h, the media was collected, and the concentration of
L-lactate was measured. Results were normalized for total cell
number.
Ketone body production. Cells were seeded in 12-well plates
in DMEM supplemented with 10% FBS. The next day, the
media was switched to DMEM without red-phenol, containing 2% FBS. After 72 h, the media was collected, and the ketoacid concentration was measured according the manufacturer’s
instructions using the β-Hydroxy-butyrate (β-HB) Assay Kit
(Biovision, #K632). Results were normalized for either total cell
number. In some experiments, Hank’s balanced salt solution
(HBSS) supplemented with 40 mM Hepes was used to initiate
cell starvation.
Statistical analysis. Statistical significance was examined
using the Student t-test. Values of p < 0.05 were considered
significant.
Disclosure of Potential Conflicts of Interest
Figure 12. Autophagy and two-compartment tumor metabolism:
Defining the roles of DRAM, LKB1 and GOLPH3. DRAM and LKB1 activate AMP-kinase in cancer-associated fibroblasts, driving autophagy,
mitophagy and mitochondrial dysfunction. Conversely, GOLPH3
expression in cancer cells mediates autophagy resistance, likely via
the induction of mitochondrial biogenesis, or the enhancement of
mitochondrial function. Thus, compartment-specific regulation of
autophagy results in a “parasitic” form of stromal-epithelial metabolic
coupling. HQ, hydroxy-chloroquine; RA, rapamycin analogs. Both chloroquine and rapamycin analogs could functionally disrupt metabolic
coupling, by simultaneously turning “on” or “off” autophagy in both
cellular compartments (cancer cells and stromal fibroblasts). CAFs,
cancer-associated fibroblasts.
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is the tumor volume, x is the length of the short axis, and y is the
length of the long axis.
Measuring tumor angiogenesis. Tumor-frozen sections were
prepared and processed, as we described previously.51 To quantify
tumor angiogenesis, CD31-positive vessels were counted in 8–10
fields from four tumors of a given experimental group (within
the central area of each tumor), using a 20x objective lens and
an ocular grid (0.25 mm2 per field). The total numbers of vessel per unit area was calculated using ImageJ, and the data was
represented graphically.
L-lactate assays. L-lactate levels were assessed according to the
manufacturer’s instructions, using the EnzyChromTM L-Lactate
Assay Kit (cat #ECLC-100, BioAssay Systems). For this purpose,
cells were seeded in 12-well plates in complete media. The next
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